Cargando…

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy

Rifaximin (RFX) treatment can attenuate not only hyperammonemia but also Enterococcus faecalis translocation and 10‐7G values, suggesting that RFX treatment may improve intestinal inflammation and result in better overall survival.[Image: see text]

Detalles Bibliográficos
Autores principales:	Tamai, Yasuyuki, Iwasa, Motoh, Eguchi, Akiko, Shigefuku, Ryuta, Kamada, Yoshihiro, Miyoshi, Eiji, Takei, Yoshiyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2021
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264230/ https://www.ncbi.nlm.nih.gov/pubmed/34263080 http://dx.doi.org/10.1002/jgh3.12596

Ejemplares similares

Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites
por: Shigefuku, Ryuta, et al.
Publicado: (2021)

Update on blood‐based biomarkers for chronic liver diseases prognosis: Literature review and institutional experience
por: Iwasa, Motoh, et al.
Publicado: (2021)

Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma
por: Tamai, Yasuyuki, et al.
Publicado: (2020)

Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans
por: Tamai, Yasuyuki, et al.
Publicado: (2022)

Elevation of enterococcus-specific antibodies associated with bacterial translocation is predictive of survival rate in chronic liver disease
por: Iwasa, Motoh, et al.
Publicado: (2022)

A Rare Presentation of Intraperitoneal Ectopic Varices Rupture
por: Shigefuku, Ryuta, et al.
Publicado: (2020)

Development of a New Index to Distinguish Hepatic Encephalopathy through Automated Quantification of Globus Pallidal Signal Intensity Using MRI
por: Tamai, Yasuyuki, et al.
Publicado: (2022)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
por: Sugimoto, Ryosuke, et al.
Publicado: (2023)

Serum Liver‐Type Fatty Acid–Binding Protein Is a Possible Prognostic Factor in Human Chronic Liver Diseases From Chronic Hepatitis to Liver Cirrhosis and Hepatocellular Carcinoma
por: Eguchi, Akiko, et al.
Publicado: (2019)

Protein Composition of Circulating Extracellular Vesicles Immediately Changed by Particular Short Time of High-Intensity Interval Training Exercise
por: Kobayashi, Yoshinao, et al.
Publicado: (2021)

A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis
por: Eguchi, Akiko, et al.
Publicado: (2022)

The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage
por: Eguchi, Akiko, et al.
Publicado: (2022)

Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab
por: Shigefuku, Ryuta, et al.
Publicado: (2022)

Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy
por: Parisse, Simona, et al.
Publicado: (2023)

Reduction in Gastrointestinal Cancers in Cirrhotic Patients Receiving Rifaximin vs Lactulose Only Therapy for Hepatic Encephalopathy
por: Patel, Ankoor H, et al.
Publicado: (2023)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Circulating Extracellular Vesicles and Their miR “Barcode” Differentiate Alcohol Drinkers With Liver Injury and Those Without Liver Injury in Severe Trauma Patients
por: Eguchi, Akiko, et al.
Publicado: (2019)

Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients
por: Fiorillo, Alessandra, et al.
Publicado: (2023)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients
por: Chang, Ji Young, et al.
Publicado: (2017)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Successful endoscopic cyanoacrylate injection therapy for ruptured duodenal varices immediately after balloon‐occluded retrograde transvenous obliteration
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Complement complex 1 subunit q‐mediated hepatic stellate cell activation with connective tissue growth factor elevation is a prognostic factor for survival in rat and human chronic liver diseases
por: Eguchi, Akiko, et al.
Publicado: (2022)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species
por: Yukawa‐Muto, Yoshimi, et al.
Publicado: (2022)

Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study
por: Lv, Xin-Yue, et al.
Publicado: (2020)

The Associations between Circulating Bile Acids and the Muscle Volume in Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
por: Kobayashi, Yoshinao, et al.
Publicado: (2017)

Neutrophil gelatinase‐associated lipocalin level is a prognostic factor for survival in rat and human chronic liver diseases
por: Yoshikawa, Kyoko, et al.
Publicado: (2017)

A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy
por: Fritz, Cassandra D.L., et al.
Publicado: (2014)

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
por: Ballester, María-Pilar, et al.
Publicado: (2022)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Sodium benzoate and rifaximin are able to restore blood-brain barrier integrity in he cirrhotic rats
por: Thabut, D, et al.
Publicado: (2015)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
por: Wu, Dong, et al.
Publicado: (2013)

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8udfp4v4bjqhbj53jpo4f0lcm3